Navigation Links
Serialization in Pharmaceuticals, a Webinar Presented by Xtalks
Date:2/22/2013

Toronto, Canada (PRWEB) February 22, 2013

Serialization provides many benefits in addition to regulatory compliance, including improving patient safety, protecting corporate reputation, enhancing corporate social responsibility, and providing a competitive advantage. There is also value in data collected through serialization efforts. Manufacturers are discovering different ways to make best use of the data being returned by their supply chain partners.

Moreover, counterfeiting of drugs and medical devices costs the pharmaceutical and medical device industry billions of dollars annually in lost revenues. This loss is amplified by the serious threats fake drugs pose to the health and safety of consumers.

A live Q&A with the audience will follow the main presentation. For more information, or to register for this event please go to http://xtks.in/xto570p.

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/2/prweb10455751.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1

Related biology technology :

1. Item Level Serialization and Anti-counterfeiting Drug Strategies
2. Antares Vision and Xyntek Inc. Announce Strategic Partnership for E-pedigree and Serialization Turn-Key Solution Delivery
3. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
4. Bioassociate Announces Initiation of Coverage on Oramed Pharmaceuticals, Inc.
5. Auxilium Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference
6. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
7. Rafarma Pharmaceuticals, Inc. Achieves Full Certification
8. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
9. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
10. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
11. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015  Pfenex Inc. (NYSE ... financial results will be released on Thursday, August 13, ... Eastern Time, Pfenex management will host a conference call ... update.  A press release outlining the financial results and ... call. Please call 1-866-376-8058 (US) or 1-412-542-4131 ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris ... announced it has selected an optimized Erk inhibitor ... in the development of a new class of ... pathway represents a prime target for therapeutic intervention ... activities and survival benefits for B-Raf and Mek ...
(Date:7/29/2015)... ... 2015 , ... Costello served as Lead Levee Design Engineering Manager for a ... Texas area from future storm surge flooding, such as occurred in Hurricane Ike in ... alternatives for providing protection, Costello also balanced socio-economic and environmental needs and ...
(Date:7/28/2015)... , July 29, 2015 A ... acquiring, rapidly developing and commercialising innovative medicines ...   Highly experienced management team; blue chip ...   Mereo BioPharma Group Ltd ("Mereo"), a ... $119m ( c. £76.5m), gross, from blue chip institutional ...
Breaking Biology Technology:Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3Preventing Storm Surge Flooding in Houston 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11
... Renovis, Inc.,(Nasdaq: RNVS ), today announced that Glass ... ISS/Risk Metrics in recommending that Renovis,stockholders vote "FOR" the ... the Special Stockholders Meeting scheduled for May,1, 2008. In ... will be,converted into the right to receive the equivalent ...
... measurement helps physicians guide therapy for ... cardiometabolic risk patients, ... apoB are now recognized as valid, accurate and recommended,methods of ... risk (CMR). The VAP(R) Cholesterol Test (Atherotech, Inc.),is the only ...
... Growth in Agriculture and Emerging ... Markets, WILMINGTON, Del., April 22 ... $1.01 in the prior year. Excluding a significant item charge in ... Sales grew 9 percent to $8.6 billion, reflecting 6 percent higher local ...
Cached Biology Technology:Glass Lewis & Co. Recommends Renovis Shareholders Vote For Merger With Evotec 2Glass Lewis & Co. Recommends Renovis Shareholders Vote For Merger With Evotec 3Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients 2Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients 3DuPont Reports First Quarter Earnings Growth of Over 20 Percent 2DuPont Reports First Quarter Earnings Growth of Over 20 Percent 3DuPont Reports First Quarter Earnings Growth of Over 20 Percent 4DuPont Reports First Quarter Earnings Growth of Over 20 Percent 5DuPont Reports First Quarter Earnings Growth of Over 20 Percent 6DuPont Reports First Quarter Earnings Growth of Over 20 Percent 7DuPont Reports First Quarter Earnings Growth of Over 20 Percent 8DuPont Reports First Quarter Earnings Growth of Over 20 Percent 9DuPont Reports First Quarter Earnings Growth of Over 20 Percent 10DuPont Reports First Quarter Earnings Growth of Over 20 Percent 11DuPont Reports First Quarter Earnings Growth of Over 20 Percent 12DuPont Reports First Quarter Earnings Growth of Over 20 Percent 13DuPont Reports First Quarter Earnings Growth of Over 20 Percent 14DuPont Reports First Quarter Earnings Growth of Over 20 Percent 15DuPont Reports First Quarter Earnings Growth of Over 20 Percent 16DuPont Reports First Quarter Earnings Growth of Over 20 Percent 17DuPont Reports First Quarter Earnings Growth of Over 20 Percent 18
(Date:7/9/2015)... , July 07, 2015 ... the addition of the "Biometrics for Banking; ... 2015-2020" report to their offering. ... contributor to this growth and the forecast is ... in revenue for companies involved in delivering biometric ...
(Date:7/8/2015)... -- Summary Pancreatic cancer is the 12th most ... a mortality rate of 10.9 deaths per 100,000 people ... has highlighted a significant need for new and improved ... the current market. A highly active pancreatic cancer ... types and mechanisms of action, which provides a striking ...
(Date:7/8/2015)... 8, 2015 The consumer products industry ... must have products such as wearables, smart wallets & other ... biometrics based devices continues to rapidly grow.  Biometrics & Wearable ... NXTD ), Google Inc. (NASDAQ: GOOG ), Apple Inc. ... GoPro, Inc. (NASDAQ: GPRO ) and Baidu Inc. (NASDAQ: ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6
... Lung cancer is the most commonly diagnosed cancer in the ... but scientists are working on ways to improve their understanding ... gather in San Diego at the San Diego Marriott Marquis ... Conference on Molecular Origins of Lung Cancer: Biology, Therapy and ...
... - Newly published research by scientists at Oregon Health ... early embryonic stem cells develop and take part in ... place at OHSU,s Oregon National Primate Research Center, has ... monkeys -- monkeys developed from stem cells taken from ...
... UCLA researchers have identified how a component of an ... the plant Hovenia, counteracts acute alcohol intoxication and withdrawal ... the action of alcohol on the brain and neurons ... side effects, in an early study with rats. Specifically, ...
Cached Biology News:Lung cancer conference to focus on new diagnostic techniques, potential treatments 2OHSU research produces the world's first primate chimeric offspring 2